Predictive biomarkers of endometrial cancer response: Results from NRG Oncology/Gynecologic Oncology Group study 86P

Douglas A. Levine,Don S. Dizon,Jay W. Carlson,Virginia L. Filiaci,Matthew A. Powell,Angeles Alvarez Secord,Krishnansu S. Tewari,David Bender,David M. O'Malley,Ashley Stuckey,Kathleen N. Moore,S.B. Dewdney,Jianjiong Gao,Fanny Dao,Robert A. Soslow,Heather A. Lankes,Carol Aghajanian

Gynecologic Oncology（2018）

引用 5|浏览49

暂无评分

摘要

Objectives: Endometrial carcinoma has many somatic mutations with potential therapeutic actionability. We correlated somatic mutations with clinical response to novel agents in advanced and recurrent endometrial cancers as part of the NRG/GOG randomized phase II trial 86P.

查看译文

关键词

endometrial cancer response,oncology/gynecologic oncology/gynecologic group study,predictive biomarkers,nrg oncology/gynecologic

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要